GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Orion Infusions Ltd (DHA:ORIONINFU) » Definitions » EBITDA Margin %

Orion Infusions (DHA:ORIONINFU) EBITDA Margin % : 12.58% (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Orion Infusions EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Orion Infusions's EBITDA for the three months ended in Dec. 2023 was BDT25.5 Mil. Orion Infusions's Revenue for the three months ended in Dec. 2023 was BDT202.7 Mil. Therefore, Orion Infusions's EBITDA margin for the quarter that ended in Dec. 2023 was 12.58%.


Orion Infusions EBITDA Margin % Historical Data

The historical data trend for Orion Infusions's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orion Infusions EBITDA Margin % Chart

Orion Infusions Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.22 11.86 13.98 13.86 12.92

Orion Infusions Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.94 11.67 15.06 13.28 12.58

Competitive Comparison of Orion Infusions's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Orion Infusions's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orion Infusions's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orion Infusions's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Orion Infusions's EBITDA Margin % falls into.



Orion Infusions EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Orion Infusions's EBITDA Margin % for the fiscal year that ended in Jun. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Jun. 2023 )/Revenue (A: Jun. 2023 )
=104.636/810.153
=12.92 %

Orion Infusions's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=25.5/202.732
=12.58 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Orion Infusions  (DHA:ORIONINFU) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Orion Infusions EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Orion Infusions's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Orion Infusions (DHA:ORIONINFU) Business Description

Traded in Other Exchanges
N/A
Address
Tejgaon Industrial Area, No. 153-154, Dhaka, BGD, 1208
Orion Infusions Ltd is a pharmaceutical company. It produces various types of intravenous fluids, rehydration solutions, electrolyte solutions, antimicrobial products, and other pharmaceutical products in Bangladesh. The products of the company include Dextrolac, Dextropac, Dextrosal, Dianak, Electro dex, fructose, Hartman, Intralipid, Manisol, Maprocin, Nidazyl, Orlev, Ortac, Plasmasol, Proliv, and Salpac. In addition, the company is also involved in activities related to cosmetics and toiletries, infrastructure development, real estate and construction, power, agro products, hospitality, textiles and garments, and aviation management sectors. Geographically, it operates in Bangladesh.

Orion Infusions (DHA:ORIONINFU) Headlines

No Headlines